Back to top

Europe begins rolling review of Eli Lilly antibodies

Europe’s drug regulator said on Thursday it had initiated a rolling review of U.S.-based Eli Lilly’s antibodies to treat COVID-19, days after saying their combination could be used in patients at high risk of progressing to severe illness.

Lilly’s bamlanivimab and etesemivab belong to a class of drugs called monoclonal antibody treatments, which mimic natural antibodies the body generates to fight infection.

This is the latest antibody treatment to earn such a review in the region and follows the European Medicines Agency’s evaluation of drugs from South Korea’s Celltrion and U.S.-based Regeneron.